Status:
UNKNOWN
Efficacy of Capecitabine With Adjuvant Radiotherapy in Treatment of Early Stages Breast Cancer (Retrospective Study).
Lead Sponsor:
Assiut University
Conditions:
Breast Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
1- Determine the efficacy and safety of concurrent capecitabine and external beam irradiation in patients with early stages breast cancer.
Detailed Description
Breast cancer is the most commonly diagnosed cancer among American women, In 2021 it is estimated that about 30%of newly diagnosed cancers in women will be breast cancer. As of January 2021, there are...
Eligibility Criteria
Inclusion
- Age of patients ≥ 18 years old patients.
- Histopathology confirmed: invasive ductal carcinoma.
- Breast conservative surgery or mastectomy.
- Early stage breast cancer patients.
- Adjuvant chemotherapy in the form of Anthracyclins based.
Exclusion
- Contraindications to radiotherapy: such as previous irradiation to chest wall or skin diseases.
- Pregnancy or lactation.
- Contraindications to capecitabine such as: severe renal impairment Or hypersensitivity to capecitabine.
Key Trial Info
Start Date :
April 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2023
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT04815616
Start Date
April 1 2023
End Date
April 1 2023
Last Update
February 1 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.